Risk scores are statistical indicators based on prescribing patterns compared to specialty peers. They are NOT allegations of fraud, misconduct, or improper care. Many legitimate medical reasons can explain outlier prescribing.
Read our methodology →Risk Flags
Risk indicators are statistical patterns, not allegations. Learn more
18,839
Total Claims
$1.4M
Drug Cost
666
Beneficiaries
$2,107
Cost/Patient
Risk Score Breakdown 15/100
Score components are additive. Read full methodology
Peer Comparison vs. 110,156 Internal Medicine providers
-95%
Opioid rate vs peers
0.1% vs 2.2% avg
+49%
Cost per patient vs peers
$2,107 vs $1,411 avg
+77%
Brand preference vs peers
18.8% vs 10.6% avg
Opioid Prescribing
0.1%
Opioid Rate
23
Opioid Claims
$324
Opioid Cost
—
Long-Acting Rate
Brand vs Generic
Brand: 3,520 claims · $1.1M
Generic: 15,231 claims · $309K
Top Prescribed Drugs
| Drug (Generic) | Claims | Cost |
|---|---|---|
| Apixaban | 605 | $172K |
| Dextromethorphan Hbr/Quinidine | 148 | $90K |
| Rifaximin | 50 | $72K |
| Emtricitab/Rilpiviri/Tenof Ala | 21 | $64K |
| Dulaglutide | 114 | $60K |
| Sitagliptin Phosphate | 148 | $41K |
| Empagliflozin | 130 | $39K |
| Umeclidinium Bromide | 76 | $29K |
| Insulin Glargine,hum.Rec.Anlog | 249 | $26K |
| Sacubitril/Valsartan | 59 | $20K |
| Semaglutide | 18 | $18K |
| Linagliptin | 56 | $16K |
| Dalfampridine | 20 | $14K |
| Rivaroxaban | 49 | $13K |
| Insulin Glargine,hum.Rec.Anlog | 163 | $12K |
Prescribing Profile
Patient Profile
77
Avg Age
48%
Female
2.93
Avg Risk Score
Explore More
Data from CMS Medicare Part D Prescriber Public Use File, 2023. Risk scores are statistical indicators, not allegations of wrongdoing.Methodology · About · Dispute this data